Immunosuppressive Tumor Microenvironment in Cervical Cancer Patients

被引:97
作者
Piersma, Sytse J. [1 ]
机构
[1] Univ Med Ctr Utrecht, Dept Med Microbiol, Room G02.667,Huispost G04.614 Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands
关键词
Cervical Cancer; Human papilloma virus; Immune response; Immune evasion; T regulatory cell;
D O I
10.1007/s12307-011-0066-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cervical cancer is caused by Human papillomavirus (HPV) in virtually all cases. These HPV-induced cancers express the viral oncogenes E6 and E7 and are therefore potentially recognized by the immune system. Despite the abundant presence of these foreign antigens, the immune system is unable to cope with the tumor. Due to the constant immunological pressure, cervical cancers can evolve different immune evasion strategies, which will be described in the current review. Several approaches for immunotherapy of cervical cancer are currently under development, which aim at inducing strong HPV-specific immunity. Besides the reinforcement of potent anti-tumor immune responses, immunotherapy could also enhance HPV-specific T regulatory cells. Supplementary strategies that neutralize an immunosuppressive milieu may have great potential. These strategies are discussed as well.
引用
收藏
页码:361 / 375
页数:15
相关论文
共 193 条
  • [1] E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I
    Ashrafi, GH
    Haghshenas, MR
    Marchetti, B
    O'Brien, PM
    Campo, MS
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2005, 113 (02) : 276 - 283
  • [2] Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma
    Attia, P
    Maker, AV
    Haworth, LR
    Rogers-Freezer, L
    Rosenberg, SA
    [J]. JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) : 582 - 592
  • [3] STATISTICAL-MODEL OF NATURAL-HISTORY OF CERVICAL NEOPLASTIC DISEASE - DURATION OF CARCINOMA INSITU
    BARRON, BA
    CAHILL, MC
    RICHART, RM
    [J]. GYNECOLOGIC ONCOLOGY, 1978, 6 (02) : 196 - 205
  • [4] SELECTIVE CHANGES IN THE IMMUNE PROFILE OF TUMOR-DRAINING LYMPH NODES AFTER DIFFERENT NEOADJUVANT CHEMORADIATION REGIMENS FOR LOCALLY ADVANCED CERVICAL CANCER
    Battaglia, Alessandra
    Buzzonetti, Alexia
    Martinelli, Enrica
    Fanelli, Mara
    Petrillo, Marco
    Ferrandina, Gabriella
    Scambia, Giovanni
    Fattorossi, Andrea
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (05): : 1546 - 1553
  • [5] Metastatic tumour cells favour the generation of a tolerogenic milieu in tumour draining lymph node in patients with early cervical cancer
    Battaglia, Alessandra
    Buzzonetti, Alexia
    Baranello, Cinzia
    Ferrandina, Gabriella
    Martinelli, Enrica
    Fanfani, Francesco
    Scambia, Giovanni
    Fattorossi, Andrea
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (09) : 1363 - 1373
  • [6] BERD D, 1987, CANCER RES, V47, P3317
  • [7] Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies
    Berger, Raanan
    Rotem-Yehudar, Rinat
    Slama, Gideon
    Landes, Shimon
    Kneller, Abraham
    Leiba, Merav
    Koren-Michowitz, Maya
    Shimoni, Avichai
    Nagler, Arnon
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (10) : 3044 - 3051
  • [8] DEVELOPMENT OF TUMOR-CELL RESISTANCE TO SYNGENEIC CELL-MEDIATED CYTOTOXICITY DURING GROWTH OF ASCITIC MASTOCYTOMA P815Y
    BIDDISON, WE
    PALMER, JC
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (01) : 329 - 333
  • [9] A distinct and unique transcriptional program expressed by tumor-associated macrophages (defective NF-κB and enhanced IRF-3/STAT1 activation)
    Biswas, SK
    Gangi, L
    Paul, S
    Schioppa, T
    Saccani, A
    Sironi, M
    Bottazzi, B
    Doni, A
    Vincenzo, B
    Pasqualini, F
    Vago, L
    Nebuloni, M
    Mantovani, A
    Sica, A
    [J]. BLOOD, 2006, 107 (05) : 2112 - 2122
  • [10] Bontkes HJ, 2000, INT J CANCER, V88, P92, DOI 10.1002/1097-0215(20001001)88:1&lt